» Articles » PMID: 17303400

Links Between Innate and Cognate Tumor Immunity

Overview
Publisher Elsevier
Date 2007 Feb 17
PMID 17303400
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer results from a tumor cell intrinsic dysregulation of oncogenes, tumor suppressor and stability genes as well as from the avoidance of immunosurveillance. A complex network of cellular interactions allows one to mount cognate anti-tumor immune responses. Recently, discoveries have been made regarding the links between innate and cognate antitumor immunity eliciting protective T-cell responses. The intricate differentiation pathway, whereby dendritic cells can efficiently mature in the tumor microenvironment, appears crucial for the priming of T cells. Transformed cells might deliver danger signals directly to the dendritic cell. Alternatively, other cell types belonging to the innate immune system can sense transformed cells through a specific set of receptors and then interact with dendritic cells to modulate their activation state. A novel subset of innate effector cells called interferon-producing killer dendritic cells are multitasking chimeras that can recognize and kill transformed cells, and undergo a maturation state of antigen presentation. Also, evidence has been produced suggesting that cell death promoted by conventional chemotherapy or radiotherapy might elicit interactions between the innate and the cognate immune system that result in anti-tumor immune responses.

Citing Articles

Regulation of Adaptive Tumor Immunity by Non-Coding RNAs.

Papaioannou E, Gonzalez-Molina M, Prieto-Munoz A, Gamez-Reche L, Gonzalez-Martin A Cancers (Basel). 2021; 13(22).

PMID: 34830805 PMC: 8616131. DOI: 10.3390/cancers13225651.


Novel chemical compound SINCRO with dual function in STING-type I interferon and tumor cell death pathways.

Kimura Y, Negishi H, Matsuda A, Endo N, Hangai S, Inoue A Cancer Sci. 2018; 109(9):2687-2696.

PMID: 29981256 PMC: 6125434. DOI: 10.1111/cas.13726.


Tumour YAP1 and PTEN expression correlates with tumour-associated myeloid suppressor cell expansion and reduced survival in colorectal cancer.

Yang R, Cai T, Wu X, Liu Y, He J, Zhang X Immunology. 2018; 155(2):263-272.

PMID: 29770434 PMC: 6142285. DOI: 10.1111/imm.12949.


The role of immune cell subpopulations in the growth and rejection of TC-1/A9 tumors in novel mouse strains differing in the H2-D haplotype and NKC domain.

Indrova M, Rossowska J, Pajtasz-Piasecka E, Mikyskova R, Richter J, Rosina J Oncol Lett. 2018; 15(3):3594-3601.

PMID: 29467880 PMC: 5795941. DOI: 10.3892/ol.2018.7763.


Targeting immune checkpoints in breast cancer: an update of early results.

Solinas C, Gombos A, Latifyan S, Piccart-Gebhart M, Kok M, Buisseret L ESMO Open. 2017; 2(5):e000255.

PMID: 29177095 PMC: 5687552. DOI: 10.1136/esmoopen-2017-000255.